1. Anti‐platelet treatment challenges in Glanzmann thrombasthenia‐clinical practice when data lacks.
- Author
-
Scafa‐Udriște, Alexandru, Popa‐Fotea, Nicoleta‐Monica, Calmac, Lucian, Onciul, Sebastian, Bataila, Vlad, Mihai, Cosmin, Ploscaru, Vlad, Uscatescu, Valentina, Gherghe, Georgiana, Grigore, Iulia, Dorobanțu, Maria, and Micheu, Miruna Mihaela
- Subjects
- *
BLOOD platelet disorders , *CORONARY artery bypass - Abstract
Anti-platelet treatment challenges in Glanzmann thrombasthenia-clinical practice when data lacks Glanzmann thrombasthenia is a rare bleeding disorder characterized by defective or low levels of glycoprotein (GP) IIb/IIIa.1 The GP IIb/IIIa receptor is activated when the platelets are stimulated by adenosine diphosphate (ADP), epinephrine, collagen, or thrombin and its presence is essential for haemostasis since it enables platelet aggregation. Cardiovascular disease treatment in bleeding disorders such as Glanzmann thrombasthenia is challenging seen that the classic treatment consisting in antiplatelets exposes this category of subjects to higher haemorrhagic events. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF